Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SMC021 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SMC021 | DRUG | - |
Inclusion Criteria: * Healthy postmenopausal female subjects, 40 to 70 years of age, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. * At Screening, and Baseline, vital signs (systolic and diastolic b...
SMC021 is an investigational small molecule being studied in healthy postmenopausal women. It is in Phase 2 clinical development for an endocrine-related condition, though the specific indication has not been disclosed. The drug is being developed by Novartis AG.
SMC021 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical development for use in healthy postmenopausal women.
SMC021 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a drug interaction study. The drug is investigational and has not been approved by regulatory authorities. It is being studied in healthy postmenopausal women.
SMC021 has one completed clinical trial, NCT00421590, titled 'Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).' This Phase 2 study enrolled 38 healthy postmenopausal women in Denmark and was a randomized, double-blind, uncontrolled trial.
SMC021 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The drug has completed one Phase 2 trial, but it remains under investigation and has not been approved for any use by regulatory authorities.